June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Development of geographic atrophy assessed by multimodal imaging in intermediate age-related macular degeneration
Author Affiliations & Notes
  • Steffen Schmitz-Valckenberg
    Ophthalmology, University of Bonn, Bonn, Germany
    John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, United States
  • Martina Braun
    Ophthalmology, University of Bonn, Bonn, Germany
  • Sarah Thiele
    Ophthalmology, University of Bonn, Bonn, Germany
  • Simon S. Gao
    Genentech, Inc., South San Francisco, California, United States
  • Hao Chen
    Genentech, Inc., South San Francisco, California, United States
  • Verena Steffen
    Genentech, Inc., South San Francisco, California, United States
  • Jian Dai
    Genentech, Inc., South San Francisco, California, United States
  • Lee Honigberg
    Genentech, Inc., South San Francisco, California, United States
  • Daniela Ferrara
    Genentech, Inc., South San Francisco, California, United States
  • Frank G Holz
    Ophthalmology, University of Bonn, Bonn, Germany
  • Marlene Sassmannshausen
    Ophthalmology, University of Bonn, Bonn, Germany
  • Footnotes
    Commercial Relationships   Steffen Schmitz-Valckenberg, Acucela (F), Alcon/Novartis (F), Alcon/Novartis (C), Alcon/Novartis (R), Allergan (C), Allergan (F), Allergan (R), Bayer (F), Bayer (R), Bioeq/Formycon (C), Bioeq/Formycon (F), Carl Zeiss MediTec (F), Carl Zeiss MediTec (R), Centervue (F), Galimedix (C), Genentech/Roche (F), Genentech/Roche (R), Heidelberg Engineering (F), Katairo (F), Optos (F); Martina Braun, Carl Zeiss MediTec (F), Centervue (F), Heidelberg Engineering (F); Sarah Thiele, Bayer (R), Carl Zeiss MediTec (F), Centervue (F), Heidelberg Engineering (F), Heidelberg Engineering (R), Novartis (R), Optos (F); Simon Gao, Genentech (E); Hao Chen, Genentech (E); Verena Steffen, Genentech (E); Jian Dai, Genentech (E); Lee Honigberg, Genentech (E); Daniela Ferrara, Genentech (E); Frank Holz, Acucela (C), Acucela (F), Acucela (R), Allergan (F), Allergan (R), Apellis (C), Apellis (R), Bayer (C), Bayer (F), Bayer (R), Bioeq/Formycon (F), Bioeq/Formycon (C), Boehringer-Ingelheim (C), Centervue (F), Ellex (R), Genentech/Roche (C), Genentech/Roche (F), Genentech/Roche (R), Geuder (C), Grayburg Vision (C), Heidelberg Engineering (C), Kanghong (C), LinBioscience (C), NightStarX (C), Novartis (C); Marlene Sassmannshausen, Carl Zeiss MediTec (F), Centervue (F), Heidelberg Engineering (F)
  • Footnotes
    Support  F. Hoffmann-La Roche Ltd, Basel, Switzerland, provided support for the study and participated in the study design, conduct of the study, and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2353. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steffen Schmitz-Valckenberg, Martina Braun, Sarah Thiele, Simon S. Gao, Hao Chen, Verena Steffen, Jian Dai, Lee Honigberg, Daniela Ferrara, Frank G Holz, Marlene Sassmannshausen; Development of geographic atrophy assessed by multimodal imaging in intermediate age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2353.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To identify and characterize precursors for development of geographic atrophy (GA) in eyes with intermediate age-related macular degeneration (iAMD).

Methods : Retrospective analysis of imaging data from patients included in a natural history study of disease progression in patients with GA, Proxima B (NCT02399072). Longitudinal multimodal imaging data, including confocal scanning laser ophthalmoscopy, fundus autofluorescence (FAF) and spectral-domain optical coherence tomography (SD-OCT), of 30 patients with iAMD in one eye and GA in the fellow eye were obtained every 6 months. Features preceding progression and conversion to advanced AMD, either GA (defined as FAF minimal lesion size ≥0.15 mm2) or choroidal neovascularization (CNV), were assessed. These included drusen, reticular pseudodrusen/subretinal drusenoid deposits (SDD), and incomplete or complete retinal pigment epithelium and outer retinal atrophy (iRORA/cRORA).

Results : During the observation period (median 17 months, range 9.2–28.0 months), out of the 30 fellow eyes with iAMD, 12 eyes converted to GA by FAF, and 2 eyes converted to CNV. Features of iRORA and cRORA were identified in all eyes that progressed to GA, demonstrating a median time interval from iRORA to cRORA of 7 months and a median time interval from cRORA to GA of 7 months. Eyes with reticular pseudodrusen (n=6) at baseline showed faster GA enlargement (mean 1.70 mm2/year) as compared to eyes with sub-RPE-drusen-associated GA and without reticular pseudo-drusen (n=5) enlargement (0.51 mm2/year). Use of the progression tool for registration of baseline to follow-up OCT scans was particularly helpful to identify features of GA development and progression.

Conclusions : In this GA cohort with unilateral iAMD, two patterns of GA development and progression were observed by multimodal imaging, either reticular pseudodrusen or drusen associated. Identification of precursor lesions and characteristics of GA occurrence and enlargement will be important for the development of future therapeutic strategies in iAMD.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×